Depemokimab: Acceptance of regulatory submissions in US (based on SWIFT-1 and SWIFT-2 trials) for asthma in H2 2024 (GSK) - May 1, 2024 - Q1 2024 Results: Acceptance of regulatory submissions in EU/China/Japan (based on SWIFT-1 and SWIFT-2 trials) for asthma in 2025
BLA • European regulatory • Japanese regulatory • Non-US regulatory • Asthma • Immunology
|